Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532072 | 1.00 | F10 (0.50) | F10F2NAMPTNR1H4 | |
| SCHEMBL5534312 | 0.94 | F10 (0.48) | F10F2NAMPTNR1H4 | |
| SCHEMBL5530440 | 0.94 | F10 (0.45) | F10F2 | |
| SCHEMBL5534305 | 0.94 | F10 (0.45) | F10F2 | |
| SCHEMBL5530431 | 0.93 | F10 (0.46) | F10F2 | |
| SCHEMBL5530427 | 0.93 | F10 (0.46) | F10F2 | |
| SCHEMBL5532255 | 0.93 | L3MBTL1 (0.48) | F10F2NAMPT | |
| SCHEMBL5527883 | 0.90 | F10 (0.48) | F10F2 | |
| SCHEMBL5541042 | 0.90 | F10 (0.47) | F10F2NAMPTNR1H4 | |
| SCHEMBL5527882 | 0.90 | F10 (0.48) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373194-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002079145-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1373194-B1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1373194-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002079145-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | SERPINC1, TFPI, F12 | F10 10/4885F2 16/4885NAMPT 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.